Share on StockTwits

Research analysts at FBR Capital Markets began coverage on shares of Achillion Pharmaceuticals (NASDAQ:ACHN) in a report released on Friday. The firm set an “outperform” rating and a $12.00 price target on the stock. FBR Capital Markets’ target price indicates a potential upside of 51.52% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Analysts at Piper Jaffray upgraded shares of Achillion Pharmaceuticals from a “neutral” rating to an “overweight” rating in a research note on Monday. They now have a $10.00 price target on the stock, up previously from $5.00. Separately, analysts at Wells Fargo & Co. upgraded shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Monday. They now have a $10.00 price target on the stock, up previously from $7.36. Finally, analysts at JMP Securities upgraded shares of Achillion Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research note on Friday, August 8th. They now have a $13.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and six have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus target price of $9.09.

Achillion Pharmaceuticals (NASDAQ:ACHN) opened at 8.44 on Friday. Achillion Pharmaceuticals has a one year low of $2.26 and a one year high of $8.68. The stock’s 50-day moving average is $7.2 and its 200-day moving average is $4.54. The company’s market cap is $825.3 million.

Achillion Pharmaceuticals (NASDAQ:ACHN) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.18) by $0.02. On average, analysts predict that Achillion Pharmaceuticals will post $-0.74 earnings per share for the current fiscal year.

Achillion Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.